Turnstone Biologics Corp. (NASDAQ:TSBX – Get Free Report) was the recipient of a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 387,800 shares, a drop of 22.1% from the September 30th total of 497,500 shares. Based on an average trading volume of 263,900 shares, the days-to-cover ratio is presently 1.5 days. Currently, 2.8% of the company’s shares are sold short.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Turnstone Biologics stock. Sei Investments Co. bought a new position in Turnstone Biologics Corp. (NASDAQ:TSBX – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 11,882 shares of the company’s stock, valued at approximately $31,000. Sei Investments Co. owned approximately 0.05% of Turnstone Biologics at the end of the most recent reporting period. 52.51% of the stock is owned by institutional investors and hedge funds.
Turnstone Biologics Stock Performance
TSBX remained flat at $0.51 on Friday. 143,019 shares of the company traded hands, compared to its average volume of 192,183. The firm has a market capitalization of $11.85 million, a price-to-earnings ratio of -0.05 and a beta of 2.26. The company’s fifty day simple moving average is $0.60 and its two-hundred day simple moving average is $1.90. Turnstone Biologics has a 52-week low of $0.44 and a 52-week high of $5.75.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on TSBX. Bank of America downgraded shares of Turnstone Biologics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $10.00 to $0.50 in a research report on Monday, October 14th. Piper Sandler cut their price objective on Turnstone Biologics from $20.00 to $3.75 and set an “overweight” rating on the stock in a research report on Monday, August 19th.
View Our Latest Report on Turnstone Biologics
Turnstone Biologics Company Profile
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.
Featured Stories
- Five stocks we like better than Turnstone Biologics
- What is a Bond Market Holiday? How to Invest and Trade
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Comparing and Trading High PE Ratio Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is a SEC Filing?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Turnstone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turnstone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.